UGN-102 is an investigational reverse thermal gel containing mitomycin, administered intravesically via a urethral catheter in an outpatient setting. This minimally invasive treatment utilizes a sustained-release, hydrogel-based formulation of mitomycin, which enhances bladder tissue ex...
Utilizing UroGen’s proprietary RTGel® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment ...
777#Background:The ATLAS and ENVISION phase 3 studies (NCT04688931/NCT05243550) treated patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel containing mitomycin. Primary efficacy and safety results were previously ...